Article Versions Notes

Sarsons CD, Gilham D, Tsujikawa LM, Wasiak S, Fu L, Rakai BD, Stotz SC, Carestia A, Sweeney M, Kulikowski E. Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells. Biomedicines. 2023; 11(10):2683. https://doi.org/10.3390/biomedicines11102683

Sarsons, Christopher D., Dean Gilham, Laura M. Tsujikawa, Sylwia Wasiak, Li Fu, Brooke D. Rakai, Stephanie C. Stotz, Agostina Carestia, Michael Sweeney, and Ewelina Kulikowski. 2023. "Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells" Biomedicines 11, no. 10: 2683. https://doi.org/10.3390/biomedicines11102683

Sarsons, C. D., Gilham, D., Tsujikawa, L. M., Wasiak, S., Fu, L., Rakai, B. D., Stotz, S. C., Carestia, A., Sweeney, M., & Kulikowski, E. (2023). Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells. Biomedicines, 11(10), 2683. https://doi.org/10.3390/biomedicines11102683